Australian Compounders Corporation Launches its Clinical Governance Committee

The Australian Compounders Corporation (ACC), a subsidiary of the Crisci Group dedicated to innovation, advancing knowledge and preserving the art and science of compounding, has reached a significant milestone with the launch of a Clinical Governance Committee.

The Clinical Governance Committee

The committee aims to reinforce the ACC’s commitment to quality and safety. The distinguished group includes:

• Three seasoned compounding pharmacists with over 60 years of combined experience.

• Two external experts: a consumer advocate with insight into compounded products and an Associate Professor specialising in pharmacology and clinical trials.

Committee Objectives

The Clinical Governance Committee will focus on:

• Enhancing Quality and Safety: Ensuring all compounded medications meet rigorous safety benchmarks.

• Supporting Regulatory Compliance: Staying ahead of evolving regulations at local and international levels.

• Risk Mitigation: Implementing robust risk management for safe, effective treatment options.

• Fostering Professional Development: Providing ongoing training to ensure best practices.

This committee represents our proactive response to increased regulatory scrutiny, ensuring the highest standards for both practitioners and patients.

Learn more about ACC, its initiatives and the Clinical Governance Committee at australiancompounders.com.au